{"prompt": "['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 26 of 169', 'Panel 4 Schedule of trial procedures: open-label tralokinumab and follow-up (continued)', 'Open-label tralokinumab treatment', 'FU1\u00b2', 'Visit', '13', '14', '15', '16', '17', '18', '19', '20', '21', '22', '23', '24', '25', '26', '27', '28', '29', '30\u00b9', '31', 'Week', '18', '20', '22', '24', '26', '28', '30', '32', '34', '36', '38', '40', '42', '44', '46', '48', '50', '52', '66', 'Safety assessments (Sections 10.4 and 11)', 'Adverse events', 'X', 'X', 'X6', 'X', 'X6', 'X', 'X6', 'X', 'X6', 'X', 'X6', 'X', 'X6', 'X', 'X6', 'X', 'X6', 'X', 'X', 'Other assessments (Section 10.5)', 'Skin swabs (S. aureus)', 'Skin swabs (microbiome)', 'Serum biomarkers (small panel)', 'Serum biomarkers (large panel)', 'Photography7', 'X', 'X', 'X', 'X', '1) Assessments also to be done at an early termination visit.', '2) All subjects will have a safety follow-up (FU1) 16 weeks after last injection of IMP, except subjects who are enrolled into the long-term extension trial', '(conducted under a separate protocol [LP0162-1337, ECZTEND]) after completion of the treatment periods.', '3)', 'Subjects', 'who', 'are eligible for home-use during open-label treatment will have to provide additional informed consent before the training at the site', '(Section 9.2); home-use will only commence after proper training of the subject or caregiver (at 3 dosing visits after the additional consent has been obtained)', 'and after 3 doses of open-label tralokinumab administered at the trial site, i.e., starting no earlier than Week 22, depending on when the subject transfers to', 'open-label treatment (selected countries only).', '4) For the first 3 IMP dosing visits in the open-label treatment period, subjects will be monitored after IMP administration for immediate drug reactions for a', 'minimum of 2 hours with vital signs taken every 30 minutes or until stable, whichever is later (Section 9.2).', '5) IMP administration at Week 52 only applicable for subjects who continue into the short-term extension of the trial (selected countries only; see Panel 5).', '6) Not applicable for subjects self-administering tralokinumab (home-use; selected countries only; Sections 7.1 and 9.2).', '7) Optional, selected trial sites only.', 'eDoc-00631888 - Version 4.0']['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 27 of 169', \"ADA, anti-drug antibodies; EASI, Eczema Area and Severity Index; ECG, electrocardiogram; IGA, Investigator's Global Assessment; IgE, immunoglobulin\", 'E;', 'IMP, investigational medicinal product; SCORAD, Scoring Atopic Dermatitis.', 'eDoc-00631888 - Version 4.0']\n\n###\n\n", "completion": "END"}